Home > Drugs A – Z > Raltegravir (By mouth)

Raltegravir (By mouth)

Treats HIV infection. HIV causes AIDS. This medicine does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Raltegravir is used together with other medicines for the treatment of the infection caused by human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is usually given to patients who have already received HIV medicines in the past. Raltegravir will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and… Read more
Brand names include
Isentress, Isentress HD
Drug classes About this
Antiretroviral Agent

What works? Research summarized

Evidence reviews

Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison

OBJECTIVE: Compare the efficacy of 2 NRTIs combined with raltegravir (RAL), efavirenz (EFV), or protease inhibitors (PI) in the management of antiretroviral-naïve HIV adult patients.

Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness [Internet]

The objective of this Rapid Response report is to evaluate the clinical and cost-effectiveness of TDF plus FTC, with or without integrase strand transfer inhibitors, as compared with other NRTI regimens with or without protease inhibitors boosted with ritonavir.

Darunavir/Cobicistat (Prezcobix) [Internet]

The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMs).

See all (17)

Summaries for consumers

Dolutegravir (Tivicay) for HIV: Dolutegravir for subsequent treatment of HIV in adults

In the spring of 2014 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed which advantages and disadvantages dolutegravir has compared with previous standard therapies in people who have already had medical treatment for HIV. One study was available to IQWiG for the purpose of this assessment. This study involved adults with HIV who had already had HIV therapy and were resistant to at least two HIV drugs.Participants in the study were divided into two groups. One group used dolutegravir, and the other was given the drug raltegravir. Both groups also received two additional drugs to treat HIV which were selected based on individual needs. A total of 724 people participated in this study and all data was analyzed after 48 weeks.

PubMed Health Blog...

read all...